Structural analogues of some highly active non-competitive AMPA antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 10, Issue 9, 2000, Pages 899-902

  Hámori, Tamás ^a   Sólyom, Sándor ^a   Berzsenyi, Pál ^a   Andrási, Ferenc ^a   Tarnawa, István ^b  

^a Institute for Drug Research Budapest   (Hungary)

^b GEDEON RICHTER LTD   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; AMPA RECEPTOR ANTAGONIST; DRUG ANALOG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CHICKEN; DRUG ACTIVITY; DRUG INHIBITION; DRUG SYNTHESIS; NONHUMAN; PURKINJE CELL; SEIZURE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; AZEPINES; BEHAVIOR, ANIMAL; BENZODIAZEPINES; BRAIN ISCHEMIA; CELLS, CULTURED; CHICKENS; ELECTROSHOCK; HUMANS; MICE; PATCH-CLAMP TECHNIQUES; PURKINJE CELLS; RATS; RECEPTORS, AMPA; RETINA; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; GALLUS GALLUS;

EID: 0343527472     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(00)00117-7     Document Type: Article

References (29)

1. Tarnawa I., Vizi E.S. Restorative Neurol. and Neurosci. 13:1998;41.
2. Tarnawa I., Berzsenyi P., Andrási F., Botka P., Hámori T., Ling I., Körösi J. Bioorg. Med. Chem. Lett. 3:1993;99.
3. Ling, I.; Podányi, B.; Hámori, T.; Sólyom, S. J. Chem. Soc. Perkin Trans. 1 1995, 1423.
4. Anderson B.A., Hansen M.M., Harkness A.R., Henry C.L., Vicenzi J.T., Zmijewski M.J. J. Am. Chem. Soc. 117:1995;12358.
5. (a) Hámori, T.; Tarnawa, I.; Sólyom, S.; Berzsenyi, P.; Birkás, E.; Andrási, F.; Ling, I.; Haskó, T.; Kapus, G.; Csuzdi, E.; Szöllösy, M.; Erdõ, F.; Simay, A.; Zólyomi, G. Ger. Offen. DE 4,428,835, 1996; Chem. Abstr. 1996, 124, 289586g.
6. (b) Csuzdi, E.; Hámori, T.; Ábrahám, G.; Sólyom, S.; Tarnawa, I.; Berzsenyi, P.; Andrási, F.; Ling, I.; Simay, A.; Gál, M.; Horváth, K.; Szentkuti, E.; Szöllõsy, M.; Pallagi, I. PCT Int. Appl. WO 97 28,163; Chem. Abstr. 1997, 127, 205597n.
7. (c) Ling, I.; Ábrahám, G.; Sólyom, S.; Hámori, T.; Tarnawa, I.; Berzsenyi, P.; Andrási, F.; Csuzdi, E.; Szöllösy, M.; Simay, A.; Pallagi, I.; Horváth, K. PCT Int. Appl. WO 97 28,135; Chem. Abstr. 1997, 127, 205596m.
8. (d) Ábrahám, G.; Csuzdi, E.; Sólyom, S.; Berzsenyi, P.; Tarnawa, I.; Andrási, F.; Ling, I.; Hámori, T.; Horváth, K.; Moravcsik, I.; Pallagi, I.; Simay, A. PCT Int. Appl. WO 99 06,408; Chem. Abstr. 1999, 130, 168401h.
9. Anderson B.A., Harn N.K., Hansen M.M., Harkness A.R., Lodge D., Leander J.D. Bioorg. Med. Chem. Lett. 9:1999;1953.
10. (a) Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Grasso, S.; Quartarone, S.; Zappalà, S.; Giust, P.; Libri, V.; Constanti, A. G. J. Med. Chem. 1997, 40, 1258.
11. (b) De Sarro, A.; De Sarro, G.; Gitto, R.; Grasso, S.; Micale, N.; Quartarone, S.; Zappalà, M. Bioorg. Med. Chem. Lett. 1998, 8, 971.
12. (c) Wang, Y.; Konkoy, C. S.; Ilyin, V. I.; Vanover, K. E.; Carter, R. B.; Weber, E.; Keana, J. F. W.; Woodward, R. M.; Cai, S. X. J. Med. Chem. 1998, 41, 2621.
13. (d) Chimirri, A.; De Sarro, G.; De Sarro, A.; Gitto, R.; Qartarone, S.; Zappalà, M.; Constanti, A.; Libri, V. J. Med. Chem. 1998, 41, 3409.
14. (d) Grasso, S.; De Sarro, G.; De Sarro, A.; Gitto, R.; Micale, N.; Zappalà, M.; Puia, G.; Baraldi, M.; De Micheli, C. J. Med. Chem. 1999, 42, 4414.
15. (a) Pelletier, J. C.; Hesson, D. P.; Jones, K. A.; Costa, A.-M. J. Med. Chem. 1996, 39, 343.
16. (b) Pei, X.-F.; Sturgess, M. A.; Valenzuele, C. F.; Maccecchini, M.-L. Bioorg. Med. Chem. Lett. 1999, 9, 539.
17. Kikuchi, H.; Kogure, K.; Toyoda, M. Chem. Lett. 1984, 341.
18. Furst A. Chem. Rev. 65:1965;51.
19. Target compounds were characterized by IR and NMR as well as by MS methods. Melting points (°C) are as follows: 14a (201-203), 14b (185-187), 14c (231-233), 14d (176-178), 14e (195-197), 14g (108-110).
20. 50 determination was performed with the molecules showing an inhibition bigger than 60%, in 3-5 concentrations (6-6 retinas at each concentration).
21. Bleakman, D.; Ballyk, B. A.; Schoepp, D. D.; Palmer, A. J.; Bath, K. P.; Scharpe, E. F.; Wooley, M. L.; Bufton, H. R.; Kamboj, R. K.; Tarnawa, I.; Lodge, D. Neuropharmacology, 1996, 35, 1689. Compounds were tested for inhibition of whole cell current induced by 5 μM AMPA in 4-6 Purkinje cells at each concentration.
22. Swinyard B.A. J. Pharmacol Exp. Ther. 106:1952;319. (10 Mice/dose and 3-4 doses were used.).
23. Goodman L.S., Scheckel C.L., Banninger R.F. J. Pharmacol. Exp. Ther. 108:1953;168. The lethality following the ip application of 130 mg/kg metrazole was evaluated. (10 Mice/dose and 3-4 doses were used.).
24. Randall L.O., Schallek W., Heise G.A., Keth E.F., Bagdon R.E. J. Pharmacol. Exp. Ther. 129:1960;163. (10 mice/dose and 3-4 doses were used.).
25. Irwin S. Psychopharmacologia. 13:1968;222. (10 mice/dose were used.).
26. Litchfield J.T., Wilcoxon F. J. Pharmacol. Exp. Ther. 96:1949;99.
27. Sydserff S.G., Cross A.J., West K.J., Green A.R. Br. J. Pharmacol. 114:1995;1631. .(n=10/dose.).
28. Zea Longe E., Weinstein R., Carlson S., Cummins R. Stroke. 20:1989;84.
29. Horváth K., Szabó H., Pátfalusi M., Berzsenyi P., Andrási F. Eur. J. Pharmacol. 183:1990;1416.